XXXX and @entity447 .

@entity1 @entity154 @entity447 @entity281 @entity1200 @entity791 @entity4777
The prevalence of overt @entity791 in @entity447 in the USA is about 3% treated @entity1 and about 2% in UK. Nevertheless up to 90% of @entity1 with @entity447 treated with commercial concentrates of factor VIII prepared from the blood of paid donors are seropositive to the @entity791 -associated virus LAV/HTLV III. Infection seems to have commenced in 1978 in USA and in 1980 in Europe. The accession rate to the symptomatic group is not known. Seropositivity is much lower in @entity1 treated with blood products derived from voluntarily donated blood but such @entity1 , even when seronegative, often show cellular @entity1200 . An additional immunosuppressive agent in factor VIII concentrates may be responsible for this and could predispose to @entity281 . @entity791 , @entity1200 and seropositivity are less common in @entity1 with @entity4777 even when treated with factor IX concentrate derived from paid donors. The reasons for this @entity154 are not known. The diagnosis, social, family and counselling problems of infected @entity1 are surveyed and the prospects for effective anti-viral or immunotherapy assessed. Treatment policies using heat-treated factor concentrates and the impact of donor screening are reviewed. It is concluded that the outlook for uninfected haemophiliacs with regard to @entity791 is now good.
